OPT - Opthea To Present at Clinical Trials at the Summit Meeting | Benzinga
MELBOURNE, Australia and PRINCETON, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that the Company will make several presentations at the Clinical Trials at the Summit (CTS) Meeting being held in Park City, Utah on June 8, 2024. Frederic Guerard, PharmD, Chief Executive Officer of Opthea, will participate in a panel, there will be two scientific presentations related to the sozinibercept (OPT-302) clinical trial program and a sponsor talk.
CTS brings together experts from around the world to discuss ongoing clinical trials and the latest data with the goal of accelerating advances in vitreoretinal care.
Opthea Presentations (in program order):
Session: Clinical Trials Addressing Neovascular AMD (nAMD)
Scientific Presentation: Implications for Targeting VEGF-C/D: Potential for Vision Gain Beyond VEGF-A Inhibition
Time: 1:02 - 1:06 pm MDT
Presenter: Megan Baldwin, PhD, MAICD, Founder, Chief Innovation Officer and Executive Director, Opthea
Scientific Presentation: Superior Functional Outcomes Beyond Standard of Care: Update on Sozinibercept Clinical Trials
Time: 1:06 - 1:10 pm MDT
Presenter: Julie Clark, MD, Senior Vice President of Clinical Development, Opthea
Sponsor Talk: Opthea Overview
Time: 1:39 – 1:49 pm MDT
Panel: Challenges of Bringing New Treatment Options to Market
Time: 3:40 - 4:00 pm MDT
Panelist: Frederic Guerard, PharmD, Chief Executive Officer, Opthea
About Opthea
Opthea (NASDAQ:OPT) is a biopharmaceutical company ...